Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
about
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerAdvances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung CancerLocoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer.Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancerPhase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factoDefining local-regional control and its importance in locally advanced non-small cell lung carcinomaRadiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer.Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancerRadiation-Induced Esophagitis is Mitigated by Soy Isoflavones.FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy21 years of biologically effective dosePooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)?Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical TrialDART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.Elevation in exhaled nitric oxide predicts for radiation pneumonitisChemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerDose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer.Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma.Challenges in optimizing chemoradiation in locally advanced non small-cell lung cancers in India.Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer.Innate Immune Pathways Associated with Lung Radioprotection by Soy Isoflavones.CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancerUse of FDG-PET in Radiation Treatment Planning for Thoracic Cancers.Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond.Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends.Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer.Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?Proton beam therapy in Japan: current and future status.Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.Dose-mass inverse optimization for minimally moving thoracic lesions.Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.The evolution of proton beam therapy: Current and future status.
P2860
Q26827571-1041C457-474C-4C06-9684-0EAE26E6CAE6Q33645619-98AD5DD9-BA20-496A-BEB6-3E96D55872EDQ33786722-B62F033E-8ACA-4BED-B72B-2A41A943DE23Q34135928-BB86DEA2-9336-49F3-AD29-1FE827752A07Q34836491-149866BE-598D-458D-9FE3-655291EB9B80Q35216097-F8D3B4B6-2E81-4FD4-9E7D-BE8AE583147CQ35568485-F3B2E23D-597A-4E59-924B-696674165F13Q35911195-4A0624BE-F3DE-4768-9C4C-FE6B419AB0DBQ35971034-1E8BB04E-CD4D-46E7-B6D8-506C9A464958Q36143838-F496641E-0A75-4492-8CC2-316B8726A16BQ36196702-A558EE03-C6F0-497C-B6F9-39A928D5643BQ36239986-DD721D4F-FDD4-4B24-A85C-F9393E046505Q36324701-20F1929E-7941-4454-ACF5-240E5D3FA4FEQ36368864-95EA16BC-F212-4B6E-A442-8593AACCF1C2Q36609568-3BAED39D-1F22-40C3-A32F-6299B50BE70AQ36673860-6604A83C-F6AD-4C38-B5A1-88D3E7E7ECE2Q36710620-798BCD00-F6B2-40C2-A2BF-64FF547C8E4DQ36766529-3B2CABDA-6AA2-4FD8-AE20-75C6C4D38C8AQ36989648-C854010E-D64D-4E19-908B-8B24E1112254Q37098334-5F17A3A8-5056-46A5-8F89-E091C0353B78Q37206363-50F2ED19-5EF8-4807-81F1-AB70B20D20F2Q37341807-DABE432A-4829-4644-921A-54097596584AQ37467273-7451343A-C94C-44F1-A3E4-95CE977E13F0Q37516506-7469C2BB-88B1-4746-9D7A-E63401923737Q37598532-8C9B1CA5-9917-4120-8107-64538B587D63Q37892578-B9A2861E-5F13-42EA-96EB-3252F63028E6Q37975010-3B5925D1-EF9B-4A13-9F68-926F0AC11149Q38016163-4476B65B-B1A2-4DB4-AC32-A04D14A94866Q38226816-0181551B-224A-4BC7-9E0B-DBDD763E1265Q38261944-B1697762-A8C1-4826-8F0F-EF947E4FC868Q38350598-0808817D-E0C4-4666-882B-6E1C3C0478F3Q38549486-CA9ED657-F2E6-41D0-BF5B-C2BB8FC7AA6CQ38830371-69E77FBE-0CD1-4A4D-9D38-A6989AF137B1Q38834703-FB17C95B-5E26-4341-8A52-17601788CA74Q39019487-844CD93E-BD5E-469C-8E70-E051F352C3C3Q39510875-12A56AD7-374F-4A06-AFB7-58FD4B9D19D0Q40491681-A5CC5A28-4763-4C10-89E5-27440F57735EQ42363788-0901FF70-369B-4AD8-9044-8539F2CB49ABQ43561521-3C8EDA40-FDAC-4E2F-AAB2-355D1D67C4DAQ49333936-C753878A-B113-4B56-9E29-DFA833827B81
P2860
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@ast
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@en
type
label
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@ast
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@en
prefLabel
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@ast
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@en
P2093
P2860
P356
P1476
Primary analysis of the phase ...... l-cell lung cancer: RTOG 0117.
@en
P2093
Elizabeth Gore
Jack Fowler
James A Purdy
Jeff M Michalski
Jeffrey D Bradley
Kyounghwa Bae
Mary V Graham
Ramaswamy Govindan
Roger Byhardt
P2860
P304
P356
10.1200/JCO.2009.27.1205
P407
P577
2010-04-05T00:00:00Z